Neuraxpharm
Privately held: no public share price · Spain
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Ublituximab(Briumvi) | Approved | CD20Monoclonal antibody | Multiple SclerosisSchizophreniaMyasthenia Gravis |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (2)
2030 (1)
January 2030 (1)
Est. primary completion 2030-01-01 · NCT07220252 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Est. primary completion 2032-05-31 · NCT04130997 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
9 June 2026Topline resultUblituximabPhase 1 topline of subcutaneous ublituximab (BRIUMVI) in myasthenia gravis
TG THERAPEUTICS, INC. · Source ↗
Financial reports
No financial reports recorded.